Crohn's disease

News

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

News

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.

R&D

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades.

News

The INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.

News

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth?

News

Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.